345 related articles for article (PubMed ID: 30314507)
1. Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review.
Davignon JL; Rauwel B; Degboé Y; Constantin A; Boyer JF; Kruglov A; Cantagrel A
Arthritis Res Ther; 2018 Oct; 20(1):229. PubMed ID: 30314507
[TBL] [Abstract][Full Text] [Related]
2. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
Meroni PL; Valesini G
BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
[TBL] [Abstract][Full Text] [Related]
3. The immunomodulatory effects of TNF-α inhibitors on human Th17 cells via RORγt histone acetylation.
Lin YC; Lin YC; Wu CC; Huang MY; Tsai WC; Hung CH; Kuo PL
Oncotarget; 2017 Jan; 8(5):7559-7571. PubMed ID: 27926504
[TBL] [Abstract][Full Text] [Related]
4. Characterization of T-Cell Receptor Repertoire in Patients with Rheumatoid Arthritis Receiving Biologic Therapies.
Chang CM; Hsu YW; Wong HS; Wei JC; Liu X; Liao HT; Chang WC
Dis Markers; 2019; 2019():2364943. PubMed ID: 31360262
[TBL] [Abstract][Full Text] [Related]
5. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
Soubrier M; Pereira B; Frayssac T; Fan A; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
Int J Rheum Dis; 2018 Nov; 21(11):1924-1932. PubMed ID: 28901727
[TBL] [Abstract][Full Text] [Related]
6. B Lymphocytes in Rheumatoid Arthritis and the Effects of Anti-TNF-α Agents on B Lymphocytes: A Review of the Literature.
Pala O; Diaz A; Blomberg BB; Frasca D
Clin Ther; 2018 Jun; 40(6):1034-1045. PubMed ID: 29801753
[TBL] [Abstract][Full Text] [Related]
7. Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis.
Navarro-Millán I; Curtis JR
Curr Opin Rheumatol; 2013 May; 25(3):384-90. PubMed ID: 23511719
[TBL] [Abstract][Full Text] [Related]
8. Anti-TNF in rheumatoid arthritis: an overview.
Radner H; Aletaha D
Wien Med Wochenschr; 2015 Jan; 165(1-2):3-9. PubMed ID: 25651945
[TBL] [Abstract][Full Text] [Related]
9. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
Manadan AM; Block JA
Am J Ther; 2008; 15(1):53-8. PubMed ID: 18223354
[TBL] [Abstract][Full Text] [Related]
10. Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series.
Umekita K; Umeki K; Miyauchi S; Ueno S; Kubo K; Kusumoto N; Takajo I; Nagatomo Y; Okayama A
Mod Rheumatol; 2015 Sep; 25(5):794-7. PubMed ID: 24252020
[TBL] [Abstract][Full Text] [Related]
11. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
Mary J; De Bandt M; Lukas C; Morel J; Combe B
J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
[TBL] [Abstract][Full Text] [Related]
12. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis.
Chauffier K; Salliot C; Berenbaum F; Sellam J
Rheumatology (Oxford); 2012 Jan; 51(1):60-8. PubMed ID: 21515629
[TBL] [Abstract][Full Text] [Related]
13. TCD4
Picchianti Diamanti A; Laganà B; Cox MC; Pilozzi E; Amodeo R; Bove M; Markovic M; Di Rosa R; Salemi S; Sorgi ML; Rosado MM; D'Amelio R
J Transl Med; 2017 Feb; 15(1):38. PubMed ID: 28222785
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors.
Naniwa T; Iwagaitsu S; Kajiura M
Int J Rheum Dis; 2018 Mar; 21(3):673-687. PubMed ID: 29314738
[TBL] [Abstract][Full Text] [Related]
15. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.
Capsoni F; Sarzi-Puttini P; Atzeni F; Minonzio F; Bonara P; Doria A; Carrabba M
Arthritis Res Ther; 2005; 7(2):R250-5. PubMed ID: 15743471
[TBL] [Abstract][Full Text] [Related]
16. TNF as a Target of Inflammation in Rheumatoid Arthritis.
Yamanaka H
Endocr Metab Immune Disord Drug Targets; 2015; 15(2):129-34. PubMed ID: 25772178
[TBL] [Abstract][Full Text] [Related]
17. Rheumatoid Arthritis - Anti-TNF.
Chaabo K; Kirkham B
Int Immunopharmacol; 2015 Aug; 27(2):180-4. PubMed ID: 25962818
[TBL] [Abstract][Full Text] [Related]
18. Bimodal Function of Anti-TNF Treatment: Shall We Be Concerned about Anti-TNF Treatment in Patients with Rheumatoid Arthritis and Heart Failure?
Kotyla PJ
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29895751
[TBL] [Abstract][Full Text] [Related]
19. T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization.
Koenders MI; Marijnissen RJ; Joosten LA; Abdollahi-Roodsaz S; Di Padova FE; van de Loo FA; Dulos J; van den Berg WB; Boots AM
Arthritis Rheum; 2012 Jun; 64(6):1762-70. PubMed ID: 22213107
[TBL] [Abstract][Full Text] [Related]
20. [Emerging therapy in rheumatoid arthritis].
Kańska U; Boratyński J
Postepy Hig Med Dosw (Online); 2008 Feb; 62():94-102. PubMed ID: 18334924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
